BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Aphios Announces Collaboration With Japanese Companies For Development Of Orally-Bioavailable Anti-Cancer Therapeutic


10/19/2005 5:11:39 PM

WOBURN, Mass.--(BUSINESS WIRE)--July 19, 2005--Aphios Corporation today announced that it has entered a Research and Development collaboration with two Japanese companies, Bio Research Corporation of Yokohama, Yokohama, Japan and Tokyo Supply, Ltd., Minato, Japan to develop an orally-bioavailble anti-cancer therapaeutic. The collaborators plan to develop a water-soluble paclitaxel prodrug. The molecule is a combination of a paclitaxel molecule, the potent anticancer drug, and a sugar molecule that enhances solubility. This molecular combination is not bioactive prior to treatment and is significantly more water-soluble than paclitaxel. The water-soluble nature of this novel therapeutic allows for oral digestion rather than intra-venous (IV) injection. After ingestion and adsorption in the gut, serum enzymes break the combined molecule down into the bioactive paclitaxel and a sugar molecule. Preclinical testing (both in in vitro cell culture experiments and in vivo animal studies) indicates that the paclitaxel prodrug is superior to paclitaxel (Taxol(R)) and equivalent to docetaxel (Taxotere(R)) in therapeutic efficacy. This paclitaxel prodrug has been patented in the United States and Japan.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES